|Day's range||0.3600 - 0.3600|
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
We think intelligent long term investing is the way to go. But that doesn't mean long term investors can avoid big...
Pfizer (PFE) suffers massively in 2019 due to aggressive business development activity, incremental currency woes and loss of exclusivity of key drug Lyrica. But it is poised to have a better 2020.
As Mylan (MYL) remained plagued with challenges in 2019, we take an insight into whether or not, the next year holds any promise for the company.
Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until February 14, 2020 to file lead plaintiff applications in a securities class action lawsuit against Mylan N.V. (NasdaqGS: MYL), if they purchased the Company’s securities between May 9, 2018 and May 6, 2019, inclusive (the "Class Period"). This action is pending in the United States District Court for the Western District of Pennsylvania.
IMPORTANT INVESTOR REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Mylan N.V.
Shareholder rights law firm Robbins LLP announces that a purchaser of Mylan N.V. (NYSE: MYL) filed a class action complaint against the company for alleged violations of the Securities and Exchange Act of 1934 between May 9, 2018 and May 6, 2019. Mylan develops and manufactures over-the-counter pharmaceutical products.
IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Mylan N.V.
FDA grants priority review to Pfizer's (PFE) sNDA seeking approval of Braftovi in combination with Erbitux as a treatment for advanced colorectal cancer.
Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Mylan N.V. (NASDAQ: MYL) between May 9, 2018 and May 6, 2019, inclusive (the "Class Period"). The lawsuit seeks to recover damages for Mylan investors under the federal securities laws.
Pfizer Inc. (NYSE: PFE) and Mylan N.V. (NASDAQ: MYL) today announced that Ian Read and James Kilts will join the Viatris board of directors upon completion of the planned combination of Mylan N.V. and Upjohn Inc., which is expected to occur in mid-2020. The Viatris board will oversee a company with a combined global presence and a mission to serve the health needs of people around the world.
Acorda's (ACOR) lead MS drug Ampyra is hit by generic competition in the United States, which is hurting the company's top line of late. Parkinson's disease drug Inbrija seems an ideal replacement.
Likelihood of a soon-to-be-signed U.S.-China trade deal, upbeat holiday season sales expectations and decent earnings have led the Nasdaq-100 ETF to a new high.
Mylan N.V. (MYL) and Pfizer Inc. (PFE) today announced that the name of the new company to be formed by the planned combination of Mylan and Upjohn, a division of Pfizer, will be Viatris (pronounced ‘viǝ-trīs). Deriving its name from Latin, Viatris embodies the new company’s goal of providing a path—“VIA”—to three—“TRIS”—core goals: expanding access to medicines, leading by innovating to meet patient needs, and being a trusted partner for the healthcare community worldwide. “The name Viatris communicates the strength of our companies’ combined heritage and our shared goal to provide the highest-quality medicines to the most patients possible,” said Michael Goettler, Group President, Upjohn, who will serve as Chief Executive Officer of Viatris, as previously announced.
Teva Pharmaceutical (TEVA) misses earnings estimate but beats the same for sales. The company increases the lower end of its 2019 sales and earnings guidance. Shares rise.
Theravance's (TBPH) third-quarter loss matches estimates while revenues miss the same in absence of product sales due to the sale of its only marketed drug Vibativ to Cumberland Pharmaceuticals.
Acorda (ACOR) posts narrower-than-expected loss with revenues also topping estimates in the third quarter. Inbrija is also off to a promising start with sales rising sequentially.
Mylan (MYL) delivered earnings and revenue surprises of 2.63% and -2.39%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?